{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:37:05Z","timestamp":1781163425786,"version":"3.54.1"},"reference-count":64,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T00:00:00Z","timestamp":1500508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2017,12]]},"abstract":"\n Aims<\/jats:title>\n \n To estimate the long\u2010term cost\u2010effectiveness of exenatide twice daily vs insulin glargine once daily as add\u2010on therapy to oral antidiabetic agents (\n OADs<\/jats:styled-content>\n ) for Chinese patients with type 2 diabetes (\n T2DM<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n The Cardiff Diabetes Model was used to simulate disease progression and estimate the long\u2010term effects of exenatide twice daily vs insulin glargine once daily. Patient profiles and treatment effects required for the model were obtained from literature reviews (English and Chinese databases) and from a meta\u2010analysis of 8 randomized controlled trials comparing exenatide twice daily with insulin glargine once daily add\u2010on to\n OADs<\/jats:styled-content>\n for\n T2DM<\/jats:styled-content>\n in China. Medical expenditure data were collected from 639 patients with\n T2DM<\/jats:styled-content>\n (aged \u226518 years) with and without complications incurred between January 1, 2014 and December 31, 2015 from claims databases in Shandong, China. Costs (2014 Chinese Yuan [\u00a5]) and benefits were estimated, from the payers\u2019 perspective, over 40 years at a discount rate of 3%. A series of sensitivity analyses were performed.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Patients on exenatide twice daily +\n OAD<\/jats:styled-content>\n had a lower predicted incidence of most cardiovascular and hypoglycaemic events and lower total costs compared with those on insulin glargine once daily +\n OAD<\/jats:styled-content>\n . A greater number of quality\u2010adjusted life years (QALYs; 1.94) at a cost saving of \u00a5117 706 gained was associated with exenatide twice daily vs insulin glargine once daily. (i.e. cost saving of \u00a560 764\/\n QALY<\/jats:styled-content>\n ) per patient.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n In Chinese patients with\n T2DM<\/jats:styled-content>\n inadequately controlled by\n OADs<\/jats:styled-content>\n , exenatide twice daily is a cost\u2010effective add\u2010on therapy alternative to insulin glargine once daily, and may address the problem of an excess of medical needs resulting from weight gain and hypoglycaemia in\n T2DM<\/jats:styled-content>\n treatment.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12991","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T04:06:45Z","timestamp":1493352405000},"page":"1688-1697","source":"Crossref","is-referenced-by-count":13,"title":["Cost\u2010effectiveness of exenatide twice daily vs insulin glargine as add\u2010on therapy to oral antidiabetic agents in patients with type 2 diabetes in China"],"prefix":"10.1111","volume":"19","author":[{"given":"Shuyan","family":"Gu","sequence":"first","affiliation":[{"name":"Centre for Health Policy Studies, School of Public Health Zhejiang University School of Medicine Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Wang","sequence":"additional","affiliation":[{"name":"Health Insurance Office, Shandong Provincial Hospital affiliated to Shandong University Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Qiao","sequence":"additional","affiliation":[{"name":"Astrazeneca Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Gao","sequence":"additional","affiliation":[{"name":"Astrazeneca Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Public Health, Shandong University Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5064-7297","authenticated-orcid":false,"given":"Hengjin","family":"Dong","sequence":"additional","affiliation":[{"name":"Centre for Health Policy Studies, School of Public Health Zhejiang University School of Medicine Zhejiang China"},{"name":"China Hospital Development Institute Shanghai Jiaotong University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,20]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00618-8"},{"key":"e_1_2_6_3_1","unstructured":"World Health Organization.Global report on diabetes.http:\/\/www.who.int\/diabetes\/global\u2010report\/en\/. Accessed April 30 2016."},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.168118"},{"key":"e_1_2_6_7_1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2015"},{"issue":"08","key":"e_1_2_6_8_1","first-page":"2","article-title":"Chinese guideline for Type 2 diabetes prevention (2013)","volume":"22","author":"Chinese Diabetes Society","year":"2014","journal-title":"Chin J Diabetes"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2478\/v10039-012-0078-7"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-8-200510180-00006"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0291"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-015-0178-3"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2361"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-13-0414"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2415"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0933"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X115757"},{"issue":"11","key":"e_1_2_6_18_1","first-page":"1195","article-title":"Incidence and cost of hypoglycemia episode in patients with type 2 diabetes mellitus (T2DM)","volume":"32","author":"Zheng Y","year":"2012","journal-title":"Chin Rural Health Serv Adm"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0145721706294259"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802715199"},{"issue":"20","key":"e_1_2_6_21_1","first-page":"1","article-title":"Medication utilization patterns among type 2 diabetes patients initiating exenatide BID or insulin glargine: a retrospective database study","volume":"13","author":"Pawaskar M","year":"2013","journal-title":"BMC Endocr Disord"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-9919"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X80350"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-004-1527-z"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-2940-y"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1067622"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165629"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1208207"},{"key":"e_1_2_6_29_1","unstructured":"World Health Organization.The world health report 2002\u2010 Chapter 5 (Some strategies to reduce risk\u2010 Technical considerations for cost\u2010effectiveness analysis).http:\/\/www.who.int\/whr\/2002\/en\/Chapter5.pdf?ua=1. Accessed January 24 2016."},{"key":"e_1_2_6_30_1","unstructured":"HanW.Initial Observation of Exenatide for Treatment of Type 2 Diabetes [Master Dissertation]. Qinghai China: Qinghai University;2011;10:22\u201023."},{"issue":"17","key":"e_1_2_6_31_1","first-page":"3645","article-title":"Effects of Byetta and insulin glargine for treatment of type 2 diabetes","volume":"33","author":"Gu L","year":"2012","journal-title":"Jilin Med J"},{"issue":"37","key":"e_1_2_6_32_1","first-page":"82","article-title":"Effects of exenatide on blood glucose and Islet function in patients with type 2 diabetes","volume":"52","author":"Kan Q","year":"2012","journal-title":"Shandong Med J"},{"issue":"11","key":"e_1_2_6_33_1","first-page":"941","article-title":"Effects of exenatide on glycemic control over 52 weeks in patients with type 2 diabetes","volume":"49","author":"Su X","year":"2014","journal-title":"Chin Pharm J"},{"issue":"9","key":"e_1_2_6_34_1","first-page":"1378","article-title":"Clinical efficacy of exenatide treating type 2 diabetes patients who are not well controlled by oral antiglycemia drugs","volume":"1","author":"Xu H","year":"2014","journal-title":"Chin J Prim Med Pharm"},{"key":"e_1_2_6_35_1","unstructured":"YuN.Effects of Exenatide on Liver Fat Content and Serum Chemerin in Obese Patients with Type 2 Diabetes. [Master Dissertations]. Shandong China: Qingdao University;2015."},{"key":"e_1_2_6_36_1","unstructured":"LiuB.Controlled Clinical Research of Obese Type 2 Diabetes Treating with Exenatide and Insulin Glargine [Master Dissertations]. Liaoning China: China Medical University;2015."},{"issue":"17","key":"e_1_2_6_37_1","first-page":"2913","article-title":"Efficacy and safety comparison on the respective combination of metformin with exenatide and insulin glargine","volume":"25","author":"Qiu C","year":"2015","journal-title":"Chin J Health Lab Technol"},{"key":"e_1_2_6_38_1","unstructured":"General Administration of Sport of China.National physique monitoring bulletin.2014.http:\/\/www.sport.gov.cn\/n16\/n1077\/n1227\/7328132.html. Accessed January 24 2016."},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.02.035"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta14360"},{"key":"e_1_2_6_41_1","unstructured":"National Bureau of Statistics of the People's Republic of China.Consumer price index of residents.http:\/\/data.stats.gov.cn\/workspace\/index?m=hgnd. Accessed May 19 2015."},{"key":"e_1_2_6_42_1","unstructured":"The Organisation for Economic Co\u2010operation and Development OECD.Conversion rates\u2010 Exchange rates.https:\/\/data.oecd.org\/conversion\/exchange\u2010rates.htm. Accessed April 25 2015."},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462312000608"},{"issue":"5","key":"e_1_2_6_44_1","first-page":"395","article-title":"Follow\u2010up effects of the increased physical activity on the glucolipid metabolic factors and medical costs in type 2 diabetic patients","volume":"22","author":"Guo H","year":"2007","journal-title":"Chin J Rehab Med"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/027298902400448902"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.00046.x"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.899207"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-007-9226-0"},{"key":"e_1_2_6_49_1","unstructured":"National Bureau of Statistics of China.Gross Domestic Product (GDP) per capita.http:\/\/data.stats.gov.cn\/easyquery.htm?cn=C01&zb=A0201&sj=2014. Accessed January 28 2016."},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2534-0"},{"issue":"8","key":"e_1_2_6_51_1","first-page":"452","article-title":"New and emerging drugs and targets for type 2 diabetes: reviewing the evidence","volume":"7","author":"Miller BR","year":"2014","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-80"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.07.009"},{"key":"e_1_2_6_54_1","first-page":"191","article-title":"Factors associated with adherence to oral antihyperglycemic monotherapy in patients with type 2 diabetes","volume":"9","author":"Tunceli K","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01581.x"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2014.06.002"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03256158"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2010.544797"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01099.x"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP47501"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X178685"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(11)72109-X"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)75005-1"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.endonu.2011.04.005"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-7-24"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12991","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.12991","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.12991","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12991","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:35:29Z","timestamp":1761888929000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,20]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/dom.12991"],"URL":"https:\/\/doi.org\/10.1111\/dom.12991","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,20]]}}}